Shopping Cart
Remove All
Your shopping cart is currently empty
PTX-35
Copy Product Info
😃Good
Catalog No. T9901A-1027
PTX-35 is a potential first-in-class agonistic monoclonal antibody targeting Tumor Necrosis Factor Receptor Superfamily Member 25 (TNFRSF25, also known as DR3). By specifically activating the TNFRSF25 signaling pathway, the compound modulates T-cell immune responses, particularly within the tumor microenvironment. In experimental studies, PTX-35 has been demonstrated to reduce the suppressive activity of regulatory T cells (Tregs) and enhance CD4+ effector T-cell responses to tumor antigens, exhibiting significant anti-tumor potential.
PTX-35
PTX-35
Copy Product Info😃Good
Catalog No. T9901A-1027
PTX-35 is a potential first-in-class agonistic monoclonal antibody targeting Tumor Necrosis Factor Receptor Superfamily Member 25 (TNFRSF25, also known as DR3). By specifically activating the TNFRSF25 signaling pathway, the compound modulates T-cell immune responses, particularly within the tumor microenvironment. In experimental studies, PTX-35 has been demonstrated to reduce the suppressive activity of regulatory T cells (Tregs) and enhance CD4+ effector T-cell responses to tumor antigens, exhibiting significant anti-tumor potential.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | PTX-35 is a potential first-in-class agonistic monoclonal antibody targeting Tumor Necrosis Factor Receptor Superfamily Member 25 (TNFRSF25, also known as DR3). By specifically activating the TNFRSF25 signaling pathway, the compound modulates T-cell immune responses, particularly within the tumor microenvironment. In experimental studies, PTX-35 has been demonstrated to reduce the suppressive activity of regulatory T cells (Tregs) and enhance CD4+ effector T-cell responses to tumor antigens, exhibiting significant anti-tumor potential. |
| In vitro | In immunological assays, PTX-35 acted as a TNFRSF25 agonist to specifically modulate T-cell subsets, demonstrating the ability to reprogram the immune response by reducing the suppressive function of Tregs while favoring effector T-cell activation [1]. |
| In vivo | In a murine melanoma model, systemic administration of PTX-35 in the presence of tumor antigens significantly enhanced CD4+ T-cell effector responses and successfully limited the suppressive influence of regulatory T cells within the tumor site [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | DR3 |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy PTX-35 | purchase PTX-35 | PTX-35 cost | order PTX-35 | PTX-35 in vivo | PTX-35 in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.